Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Ozaslan E. | Topaloglu U.S. | Inanc M. | Erdem U.G. | Demir H. | Arpaci E. | Seker M.M.

Purpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were als? given irin?tecan and/?r ?xaliplatin c?mbined with fluor?pyrimidine±bevacizumab. Tumor resp?nse and survival were evaluated using RECIST and Kaplan-Meier meth?d respectively. Results: Sixty patients were included this study. Cetuximab plus FOLFOX w ...Daha fazlası

İnceleme 2017 Journal of B.U.ON.22 ( 4 ) , pp. 8 - 868 651 Görüntülenme

Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish oncology group

Sedef A.M. | Kose F. | Sumbul A.T. | Besen A.A. | Hacioglu B. | Gunaldi M. | Nayir E.

Purpose: Advanced gastric cancer has a dismal prognosis. Platin/5-fluorouracil (PF) combination chemotherapy is the main treatment modality for metastatic gastric cancer patients. Third drug addition to PF is a controversial issue. The aim of this study was to evaluate the predictive role of tumor localization and histopathology on choosing three- or two-drug combination regimens. Methods: This study was designed as a hospital-based retrospective observational case-series study. A total of 516 patients with advanced gastric cancer has been treated at eight different oncology centers in Turkey ...Daha fazlası

Makale 2019 Journal of B.U.ON.24 ( 2 ) , pp. 6 - 655 333 Görüntülenme

A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with ras-wild metastatic colorectal cancer: A collaborative study by Turkish oncology group (tog)

Degirmencioglu S. | Tanriverdi O. | Menekse S. | Dogan M. | Hacioglu B. | Oktay E. | Erdem D.

Purpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab. Methods: This retrospective multicenter observational study involved a total of 238 patients who received chemotherapy in combination with either bevacizumab or cetuximab or panitumumab as first-line therapy for KRAS wild-type metastatic colorectal cancer. Patients with full medical records having pathological diagnosis of CRC adenocarcinoma were ...Daha fazlası

Makale 2019 Journal of B.U.ON.24 ( 1 ) , pp. 2 - 248 682 Görüntülenme

Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: A retrospective analysis

Ergun Y. | Ozdemir N.Y. | Guner E.K. | Esin E. | Sendur M.A. | Koksoy E.B. | Demirci N.S.

Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer. Methods: Data of 664 patients diagnosed with metastatic pancreatic cancer between January 2007 and December 2016 from seven oncology cen ...Daha fazlası

Makale 2018 Journal of B.U.ON.23 , pp. 1 - 121 315 Görüntülenme

The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study

Saip P. | Keskin S. | Ozkan M. | Kaplan M.A. | Aydogan F. | Gonullu Demirag G. | Uzunoglu S.

Purpose: To determine the time elapsed between the first notification of the disease and the access to the diagnosis and treatment modalities and the associated factors infernale patients with breast cancer in Turkey. Methods: Data was acquired from a questionnaire involving 535 patients who applied to 14 various oncology clinics in Turkey between 1st and 28 th of February 2010. Analyses were performed by the participating clinics and were divided into 3 groups: centers located in metropolitan areas formed group 1 (n=161), those located in Marmara and central Anatolia region formed group 2 (n= ...Daha fazlası

Makale 2011 Journal of B.U.ON.16 ( 4 ) , pp. 6 - 671 271 Görüntülenme

Cutaneous melanoma in Turkey: Analysis of 1157 patients in the Melanoma Turkish Study

Abali H. | Celik I. | Karaca B. | Turna H. | Saglam E.K. | Akman T. | Oztop I.

Purpose: To develop a large Turkish National Melanoma registry in order to define demographic and clinicopathologic characteristics of patients with melanoma. Methods: The data was collected from 1635 patients with melanoma through a web-based registry system in 22 centers. Herein we present the results of 1157 patients with cutaneous melanoma. Results: The patient median age was 56.4 years and 646 (55.8%) were males. The commonest subtype was superficial spreading type (357, 30.9%). The commonest primary site was the lower extremities (N=353, 30.5%). The most common Breslow thickness was 1-2 ...Daha fazlası

Makale 2015 Journal of B.U.ON.20 ( 4 ) , pp. 1 - 1141 470 Görüntülenme

The influence of cisplatin, doxorubicin, pegylated doxorubicin, oxaliplatin and gemcitabine on mahlavu cell line

Ilikhan S.U. | Bilici M. | Sahin H. | Akca A.S.D. | Engin H. | Bilir C. | Sevinc N.

Purpose: Hepatocellar carcinoma (HCC) remains a major health problem being the third leading cause of deaths due to cancer worldwide. Because HCC is known to be highly resistant to conventional systemic therapies, single-agent or combination of systemic therapies have been investigated Today, sorafenib, a multikinase inhibitor, is the only approved systemic agent for the first line treatment of advanced HCC. In this study, we aimed to investigate the influence of different concentrations of cisplatin, doxorubicin, pegylated doxorubicin (PLD), oxaliplatin and gemcitabine by applying these agent ...Daha fazlası

Makale 2015 Journal of B.U.ON.20 ( 2 ) , pp. 6 - 613 171 Görüntülenme

Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: Report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Aydin D. | Sendur M.A. | Kefeli U. | Unal O.U. | Tastekin D. | Akyol M. | Tanrikulu E.

Purpose: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Since these are rarely encountered tumors, there are limited numbers of studies investigating systemic treatment in advanced SBA. The purpose of this study was to evaluate the prognostic factors and systemic treatments in patients with advance SBA. Methods; Seventy-one patients from 18 Centers with advanced SBA were included in the study. Fifty-six patients received one of the four different chemotherapy regimens as first-line therapy and 15 patients were treated with best supportive c ...Daha fazlası

Makale 2016 Journal of B.U.ON.21 ( 5 ) , pp. 1 - 1249 102 Görüntülenme

Filtreler

Koleksiyon [3]

İlgili Araştırmacılar [3]

Tam Metin [1]

Yazar [54]

Yayın Türü [2]

Yayın Yılı [6]

Yayın Dili [1]

Dergi Adı [1]

Yayıncı [1]

Konu Başlıkları [31]